Trial Profile
An Open-Label, Single-Dose Study to Assess the Absolute Oral Bioavailability and Pharmacokinetics of JNJ-28431754 (Canagliflozin) Administered as a 300-mg Oral Tablet and an Intravenous Microdose of 10 mcg 14C-canagliflozin in Healthy Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Nov 2015
Price :
$35
*
At a glance
- Drugs Canagliflozin (Primary) ; Canagliflozin (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 13 Jul 2010 New trial record